Yahoo Web Search

    • A Short Delay Is Still Bad News for AbbVie | The Motley Fool

      The Motley Fool· 4 days ago

      The FDA extended the review for AbbVie's (NYSE:ABBV) Rinvoq as a treatment for psoriatic arthritis. Brian Orelli: So, last week, AbbVie said that the FDA is extending its review of Rinvoq as a treatment for psoriatic arthritis.

    • Visteon Looks Good, but Its Shares Are Too Pricey

      Barron s Online· 21 hours ago

      Visteon is a unique, pure-play [automotive] cockpit electronics provider, primed to leverage secular demand for modular digital clusters and displays, scalable infotainment systems, and electric ...